A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion

NCT04548843 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No recruitment

Conditions

Primary Mitochondrial Diseases

Interventions

PROCEDURE: Bone Marrow mobilization
PROCEDURE: Apheresis
BIOLOGICAL: MNV-BM-PLC infusion

Sponsor

Minovia Therapeutics Ltd.